参考文献/References:
[1] Heidenreich PA,Bozkurt B,Aguilar D,et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation,2022,145(18):e895-e1032.
[2] Emmons-Bell S,Johnson C,Roth G. Prevalence,incidence and survival of heart failure:a systematic review[J]. Heart,2022,108(17):1351-1360.
[3] Goldhaber SZ. Venous thromboembolism in heart failure patients:pathophysiology,predictability,prevention[J]. J Am Coll Cardiol,2020,75(2):159-162.
[4] Rivas A,Lauw MN,Schnabel RB,et al. Stroke and thromboembolism in patients with heart failure and sinus rhythm:a matter of risk stratification?[J]. Thromb Haemost,2022,122(6):871-878.
[5] Fanola CL,Norby FL,Shah AM,et al. Incident heart failure and long-term risk for venous thromboembolism[J]. J Am Coll Cardiol,2020,75(2):148-158.
[6] Feigin VL,Brainin M,Norrving B,et al. World Stroke Organization (WSO):global stroke fact sheet 2022[J]. Int J Stroke,2022,17(1):18-29.
[7] Diener HC,Easton JD,Hart RG,et al. Review and update of the concept of embolic stroke of undetermined source[J]. Nature Reviews Neurology,2022,18(8):455-465.
[8] Savarese G,Giugliano RP,Rosano GM,et al. Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure:a meta-analysis[J]. JACC Heart Fail,2016,4(11):870-880.
[9] Siniarski A,G?secka A,Borovac JA,et al. Blood coagulation disorders in heart failure:from basic science to clinical perspectives[J]. J Card Fail,2023,29(4):517-526.
[10] Schafer A,Flierl U,Bauersachs J. Anticoagulants for stroke prevention in heart failure with reduced ejection fraction[J]. Clin Res Cardiol,2022,111(1):1-13.
[11] Redfield MM,Borlaug BA. Heart failure with preserved ejection fraction:a review[J]. JAMA,2023,329(10):827-838.
[12] Savarese G,Stolfo D,Sinagra G,et al. Heart failure with mid-range or mildly reduced ejection fraction[J]. Nat Rev Cardiol,2022,19(2):100-116.
[13] Mann DL,Felker GM. Mechanisms and models in heart failure:a translational approach[J]. Circ Res,2021,128(10):1435-1450.
[14] Carlisle MA,Fudim M,Devore AD,et al. Heart failure and atrial fibrillation,like fire and fury[J]. JACC Heart Fail,2019,7(6):447-456.
[15] Skrebelyte-Strom L,Ronning OM,Dahl FA,et al. Prediction of occult atrial fibrillation in patients after cryptogenic stroke and transient ischaemic attack:PROACTIA[J]. Europace,2022,24(12):1881-1888.
[16] Liu C,Chen S,Zhang H,et al. Bioinformatic analysis for potential biological processes and key targets of heart failure-related stroke[J]. J Zhejiang Univ Sci B,2021,22(9):718-732.
[17] Adelborg K,Szepligeti S,Sundboll J,et al. Risk of stroke in patients with heart failure:a population-based 30-year cohort study[J]. Stroke,2017,48(5):1161-1168.
[18] Chou YL,Liou JT,Cheng CC,et al. The association of ischaemic stroke in patients with heart failure without atrial flutter/fibrillation[J]. Heart,2020,106(8):616-623.
[19] Massie BM,Collins JF,Ammon SE,et al. Randomized trial of warfarin,aspirin,and clopidogrel in patients with chronic heart failure:the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial[J]. Circulation,2009,119(12):1616-1624.
[20] Zannad F,Anker SD,Byra WM,et al. Rivaroxaban in patients with heart failure,sinus rhythm,and coronary disease[J]. N Engl J Med,2018,379(14):1332-1342.
[21] Mehra MR,Vaduganathan M,Fu M,et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure,coronary artery disease,and sinus rhythm:the COMMANDER HF trial[J]. Eur Heart J,2019,40(44):3593-3602.
[22] Ferreira JP,Lam CSP,Anker SD,et al. Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm:an analysis from the COMMANDER-HF trial[J]. Eur J Heart Fail,2021,23(4):648-656.
[23] Greenberg B,Neaton JD,Anker SD,et al. Association of rivaroxaban with thromboembolic events in patients with heart failure,coronary disease,and sinus rhythm:a post hoc analysis of the COMMANDER HF trial[J]. JAMA Cardiol,2019,4(6):515-523.
[24] Branch KR,Probstfield JL,Eikelboom JW,et al. Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease[J]. Circulation,2019,140(7):529-537.
[25] Merkler AE,Pearce LA,Kasner SE,et al. Left ventricular dysfunction among patients with embolic stroke of undetermined source and the effect of rivaroxaban vs aspirin:a subgroup analysis of the NAVIGATE ESUS randomized clinical trial[J]. JAMA Neurol,2021,78(12):1454-1460.
[26] Beggs SAS,R?rth R,Gardner RS,et al. Anticoagulation therapy in heart failure and sinus rhythm:a systematic review and meta-analysis[J]. Heart,2019,105(17):1325-1334.
[27] Li W,Seo J,Kokkinidis DG,et al. Efficacy and safety of vitamin-K antagonists and direct oral anticoagulants for stroke prevention in patients with heart failure and sinus rhythm:an updated systematic review and meta-analysis of randomized clinical trials[J]. Int J Stroke,2023,18(4):392-399.
[28] Reddin C,Judge C,Loughlin E,et al. Association of oral anticoagulation with stroke in atrial fibrillation or heart failure:a comparative meta-analysis[J]. Stroke,2021,52(10):3151-3162.
[29] Mcdonagh TA,Metra M,Adamo M,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J,2021,42(36):3599-3726.
[30] Seferovic PM,Ponikowski P,Anker SD,et al. Clinical practice update on heart failure 2019:pharmacotherapy,procedures,devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail,2019,21(10):1169-1186.
[31] Tsutsui H,Ide T,Ito H,et al. JCS/JHFS 2021 Guideline focused update on diagnosis and treatment of acute and chronic heart failure[J]. J Card Fail,2021,27(12):1404-1444.
[32] Hjalmarsson C,Fu M,Zverkova Sandstrom T,et al. Risk of stroke in patients with heart failure and sinus rhythm:data from the Swedish Heart Failure Registry[J]. ESC Heart Fail,2021,8(1):85-94.
[33] Kondo T,Abdul-Rahim AH,Talebi A,et al. Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation[J]. Eur Heart J,2022,43(42):4469-4479.
[34] Zhu W,Cao Y,Ye M,et al. Essen stroke risk score predicts clinical outcomes in heart failure patients with preserved ejection fraction:evidence from the TOPCAT trial[J]. Thromb Haemost,2022,123(1):85-96.
[35] Liu X,Abudukeremu A,Yu P,et al. Usefulness of B-type natriuretic peptide for predicting the risk of stroke in patients with heart failure with preserved ejection fraction[J]. J Am Heart Assoc,2022,11(15):e024302.
[36] Packer M. HFpEF is the substrate for stroke in obesity and diabetes independent of atrial fibrillation[J]. JACC Heart Fail,2020,8(1):35-42.
[37] Son MK,Park JJ,Lim NK,et al. Impact of atrial fibrillation in patients with heart failure and reduced,mid-range or preserved ejection fraction[J]. Heart,2020,106(15):1160-1168.
[38] Rizas KD,Freyer L,Sappler N,et al. Smartphone-based screening for atrial fibrillation:a pragmatic randomized clinical trial[J]. Nat Med,2022,28(9):1823-1830.
[39] Matsushita K,Ballew SH,Wang AY,et al. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease[J]. Nat Rev Nephrol,2022,18(11):696-707.
[40] Khan MS,Shahid I,Anker SD,et al. Albuminuria and heart failure:JACC state-of-the-art review[J]. J Am Coll Cardiol,2023,81(3):270-282.
[41] Harrington J,Carnicelli AP,Hua K,et al. Direct oral anticoagulants versus warfarin across the spectrum of kidney function:patient-level network meta-analyses from COMBINE AF[J]. Circulation,2023,147(23):1748-1757.
[42] Piccini JP,Caso V,Connolly SJ,et al. Safety of the oral factor Ⅺa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF):a multicentre,randomised,double-blind,double-dummy,dose-finding phase 2 study[J]. Lancet,2022,399(10333):1383-1390.
[43] Rao SV,Kirsch B,Bhatt DL,et al. A multicenter,phase 2,randomized,placebo-controlled,double-blind,parallel-group,dose-finding trial of the oral factor Ⅺa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction[J]. Circulation,2022,146(16):1196-206.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(12):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(12):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(12):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(12):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(12):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(12):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(12):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(12):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(12):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(12):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]